New advances in pharmacogenomics

Current Opinion in Chemical Biology

Volumn 4, Issue 4, 2000, Pages 440-444

  Destenaves, Benoit ^a   Thomas, François ^a  

^a Genomic Research Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATRELEUTON; CLARITHROMYCIN; CLOZAPINE; CYTOCHROME P450; FLUOROURACIL; FLUVOXAMINE; HYDROCHLOROTHIAZIDE; INSULIN; LIPOXYGENASE INHIBITOR; MERCAPTOPURINE; NEUROLEPTIC AGENT; OMEPRAZOLE; PRAVASTATIN; SALBUTAMOL; WARFARIN; ZILEUTON;

ACUTE LYMPHOCYTIC LEUKEMIA; ASTHMA; BLEEDING TENDENCY; CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; GENE MUTATION; GENETIC VARIABILITY; GENOME; GENOTYPE; HUMAN; LIVER TOXICITY; MENTAL DISEASE; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

EID: 0033856535     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(00)00101-0     Document Type: Review

References (41)

1. Drug-metabolism research challenges in the new millennium: Individual variability in drug therapy and drug safety
2. Partial response to antipsychotic treatment: The patient with enduring symptoms
3. Evidence of interferon β-1a dose response in relapsing-remitting MS
4. Counting the costs of drug-related adverse events
5. Familial occurrence of hypersensitivity to phenytoin
6. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits
7. Prospects for whole-genome linkage disequilibrium mapping of common disease genes
8. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
9. High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays
10. Can pharmacogenomics make a difference in drug development?
11. Population choice in mapping genes for complex diseases
12. As consortium plans free SNP map of human genome
13. A 4-Mb high-density single nucleotide polymorphism-based map around APOE
14. Proteomics in drug discovery
15. Reading bits of genetic information: Methods for single-nucleotide polymorphism analysis
16. Direct genetic analysis by matrix-assisted laser desorption/ionization mass spectrometry
17. High density synthetic oligonucleotide arrays
18. Pharmacogenomics: Translating functional genomics into rational therapeutics
19. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
20. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics
21. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
22. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
23. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
24. Dihydropyrimidine dehydrogenase activity: Prognostic partner of 5-fluorouracil?
25. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
26. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
27. Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy
28. Association of cg2 and pfmdr1 genotype with chloroquine resistance in field samples of Plasmodium falciparum from Nigeria
29. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization
30. Pharmacogenomics: Will the regulators approve?
31. Alternative strategies in drug development: Clinical pharmacological aspects
32. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
33. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group
34. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
35. T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability
36. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
37. Gain of function mutation of the alpha7 nicotinic receptor: Distinct pharmacology of the human alpha7V274T variant
38. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
39. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study
40. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity